刘诚

2017-06-19

刘诚博士毕业于北京大学生命科学学院,在美国伯克利加州大学获得分子与细胞生物学博士学位。1996到2006年刘博士任职于Chiron (后被Novartis诺华收购),在此期间作为新药研究部首席科学家,主导研发针对恶性乳腺癌骨转移的CSF1抗体疗法。

2006年刘诚博士创办了Eureka Therapeutics (优瑞科生物技术公司) 并担任公司总裁至今。公司总部坐落在美国生物医药产业最活跃的旧金山湾区,并在北京清华科技园设立有全资子公司。从3个人起步,公司到今天已发展成为拥有50多名科研人员的专攻癌症免疫治疗创新药物、并形成产品序列的研发公司。优瑞科在癌症免疫治疗领域拥有多方面的领先技术,在国际上获得了广泛认可。多家全球医药公司巨头(包括诺华,勃林格殷格翰, 朱诺等),以及一流癌症中心(包括斯坦福大学,纽约纪念斯隆-凯特琳癌症中心, 希望之城国家医学中心),都和优瑞科签署了合作研发创新性免疫治疗新药的协议。刘诚博士拥有逾30项美国及国际专利,并于2007年获得美国国会颁发的生命科学特殊贡献奖。

Dr. Liu received his B.S. in Cell Biology and Genetics from Beijing University and a Ph.D. in Molecular Cell Biology from the University of California, Berkeley.  From 1996 to 2006, Dr. Liu was a Principal Scientist in antibody drug discovery at Chiron (now Novartis), where he championed anti-CSF1 antibody program for treatment of bone metastasis to human clinical trials. 

Since 2006, founder and CEO of Eureka Therapeutics, Dr. Liu followed his passion and strived to make a difference in the cancer therapeutics world.  With his vision, he developed a company of three into a team of more than fifty highly-experienced world class scientists.  Headquartered in San Francisco Bay Area, the biotech hot spot in US, Eureka continued to expand its presence and established a wholly owned subsidiary in Beijing Tsinghua Science Park.  With a wide range of leading-edge technologies in the field of cancer immunotherapy, Eureka is widely recognized domestically as well as internationally.  Multiple big pharmaceutical companies (Novartis, Boehringer Ingelheim, Juno, etc.) as well as top cancer centers (including Stanford University Medical School, Memorial Sloan-Kettering Cancer Center, City of Hope National Medical Center, etc.) have collaborated with Eureka to develop innovative immunotherapies. Dr.Liu is the inventor of more than 30 issued US and international patents in drug discovery.  In 2007, he was awarded Special US Congressional Recognition for his contributions to improving human health. 




上一篇:冯强
下一篇:曾钢
Powered by 飞色网络